DrugPatentWatch Database Preview
Details for Patent: 8,188,276
Email this page to a colleague
See Plans and PricingWhich drugs does patent 8,188,276 protect, and when does it expire?
Patent 8,188,276 protects ZYKADIA and is included in two NDAs.
This patent has one hundred and one patent family members in thirty-one countries.
Summary for Patent: 8,188,276
| Title: | 2,4-pyrimidinediamine compounds and their uses |
| Abstract: | The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. |
| Inventor(s): | Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Payan; Donald G (Hillsborough, CA), Molineaux; Susan (San Mateo, CA), Holland; Sasha J (San Francisco, CA), Clough; Jeffrey Wayne (Redwood City, CA), Keim; Holger (Irvine, CA), Bhamidipati; Somasekhar (Foster City, CA), Sylvain; Catherine (Burlingame, CA), Li; Hui (Santa Clara, CA), Rossi; Alexander B (Reedsport, OR) |
| Assignee: | Rigel Pharmaceuticals, Inc. (South San Francisco, CA) |
| Application Number: | 12/363,537 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,188,276
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ZYKADIA | ceritinib | CAPSULE;ORAL | 205755-001 | Apr 29, 2014 | DISCN | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Novartis | ZYKADIA | ceritinib | TABLET;ORAL | 211225-001 | Mar 18, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,188,276
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 451104 | Start Trial | |||
| Austria | 524184 | Start Trial | |||
| Australia | 2003208931 | Start Trial | |||
| Australia | 2003265336 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
